Leveraging innate cell engagers for lymphoma treatment
European Pharmaceutical Review
DECEMBER 28, 2023
Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. We received encouraging feedback from the US Food and Drug Administration (FDA) on the trial design and potential for accelerated approval.
84 
Let's personalize your content